Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Allogene Therapeutics (NASDAQ: ALLO) will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close.
Rhea-AI Summary
Allogene Therapeutics (NASDAQ: ALLO) will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
According to the company, the listen-only webcast will be available on its investor website, with a replay accessible for about 30 days. Registered participants who request to speak will receive a personal PIN.
Details
News Market Reaction – ALLO
On Mar 2, the day this news came out, ALLO closed 4.68% below the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Earnings date
- March 12, 2026
- Scheduled Q4 and full-year 2025 results release
- Conference call time PT
- 2:00 p.m. PT
- Start time for earnings call
- Conference call time ET
- 5:00 p.m. ET
- Start time for earnings call
- Webcast replay period
- approximately 30 days
- Replay availability on company website
Historical Context
-
Outlined participation in two Q1 2026 investor conferences.
-
Positioned 2026 as program-defining with multiple H1 2026 readouts.
-
Favorable ruling confirming cema-cel control and commercialization path.
-
Announced three late-2025 investor conference appearances.
-
Reported Q3 2025 financials and key clinical milestones timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
allogeneic car t medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended September 30, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.